Search results for "Kinase"

showing 10 items of 2635 documents

Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN.

2011

The tumor suppressor PTEN is a phosphatase using FAK and Shc as direct substrates, and Akt as a key effector via PIP3. PTEN regulates cell migration and may influence metastases. We quantified PTEN in 135 clear cell renal cell carcinomas (ccRCC) by Western blot analysis and found statistically significant lower PTEN expression in patients who died, usually caused by metastases, within 5 years after surgery, compared to those surviving this time period. In athymic mice, PTEN transfected 786-O cells were injected into the tail vein and metastatic load of the lungs was quantified. We observed a strongly reduced metastatic load after PTEN transfection. For analyses of the PTEN activities, trans…

AdultMaleCancer ResearchSrc Homology 2 Domain-Containing Transforming Protein 1PhosphataseTransplantation HeterologousMice NudeBiologyMiceCell MovementTumor Cells CulturedPTENAnimalsHumansNeoplasm MetastasisPhosphorylationProtein kinase BCarcinoma Renal CellAgedAged 80 and overOncogenePTEN PhosphohydrolaseCell migrationCell cycleMiddle AgedPrognosisSurvival AnalysisKidney NeoplasmsGene Expression Regulation NeoplasticOncologyShc Signaling Adaptor ProteinsLipid phosphatase activityCancer researchbiology.proteinPhosphorylationFemaleInternational journal of oncology
researchProduct

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases

2008

Male breast cancer (MBC) is a rare and poorly known disease. Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC. Interestingly, BRCA2 germ-line rearrangements have been described in high-risk breast/ovarian cancer families which included at least one MBC case. Germ-line mutations of CHEK2 gene have been also implicated in inherited MBC predisposition. The CHEK2 1100delC mutation has been shown to increase the risk of breast cancer in men lacking BRCA1/BRCA2 mutations. Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate c…

AdultMaleCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1male breast cancerProtein Serine-Threonine KinasesBiologychek2medicine.disease_causeBreast Neoplasms Malebrca1Breast cancerbrca2medicineHumansBRCA1/BRCA2germ-line mutationsMultiplex ligation-dependent probe amplificationmlpaskin and connective tissue diseasesneoplasmsCHEK2Germ-Line MutationGene RearrangementMutationCancerGene rearrangementmedicine.diseaseCheckpoint Kinase 2Oncologylarge genomic rearrangementsMale breast cancerCancer researchbrca1; brca2; chek2; germ-line mutations; large genomic rearrangements; male breast cancer; mlpaBreast diseaseBreast Cancer Research and Treatment
researchProduct

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

2012

Abstract Background Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC). Methods OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularOrganic Cation Transport ProteinsHepatocellular carcinomaBlotting WesternDown-RegulationOCT3Real-Time Polymerase Chain ReactionOCT1lcsh:RC254-282SLC22A3Downregulation and upregulationInternal medicineGeneticsmedicineHumansRNA MessengerHCCTyrosineSLC22A3CytotoxicitySLC22A1AgedAged 80 and overOrganic cation transport proteinsbiologybusiness.industryLiver NeoplasmsOrganic Cation Transporter 1TransporterMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisNeoplasm ProteinsEndocrinologyOncologyHepatocellular carcinomaCancer researchbiology.proteinFemalebusinessTyrosine kinaseResearch ArticleBMC Cancer
researchProduct

The EORTC module for quality of life in patients with thyroid cancer: phase III

2017

The purpose of the study was to pilot-test a questionnaire measuring health-related quality of life (QoL) in thyroid cancer patients to be used with the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire EORTC QLQ-C30. A provisional questionnaire with 47 items was administered to patients treated for thyroid cancer within the last 2 years. Patients were interviewed about time and help needed to complete the questionnaire, and whether they found the items understandable, confusing or annoying. Items were kept in the questionnaire if they fulfilled pre-defined criteria: relevant to the patients, easy to understand, not confusing, few missing values, neither …

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismPilot ProjectsIodine Radioisotopes03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeInternal medicineSurveys and QuestionnairesMedicineHumansIn patientThyroid NeoplasmsThyroid cancerProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryCancerMiddle Agedmedicine.diseasehumanitiesSurgeryOncology030220 oncology & carcinogenesisQuality of LifeFemalebusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]
researchProduct

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence …

2010

The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with 'myelodysplastic syndrome with isolated del(5q)' (median age 74 years; 60 females). In all, 60 (68%) patients were followed up to the time of their death. Overall median survival was 66 months; leukemic transformation was documented in five (5.7%) cases. Multivariable analysis identified age >or=70 years (P=0.01), transfusion need at diagnosis (P=0.04) and dysgranulopoiesis (P=0.02) as independent predictors of shortened survival; the presence of zero (low risk), one (intermediate risk) or >or=2 (high risk) risk factors corresponded to median survivals of 102, 52 and 27 months, r…

AdultMaleCancer Researchmedicine.medical_specialtyIDH1Biology5q-World Health OrganizationPolymerase Chain ReactionGastroenterologyIDH2ironInternal medicineMyelodysplastic Syndrome with Isolated del(5q)medicineHumansSurvival rateAgedAged 80 and overThrombopoietin receptorHematologyMyelodysplastic syndromesferritinHematologyJanus Kinase 2Middle AgedPrognosismedicine.diseaseIsocitrate DehydrogenaseSurvival RateLeukemiaCell Transformation NeoplasticOncologyMyelodysplastic SyndromesMutationImmunologyChromosomes Human Pair 5Original ArticleFemaleChromosome DeletionReceptors ThrombopoietinLeukemia
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Sublingual administration of captopril in patients with acute myocardial ischemia.

1991

Summary: To investigate the anti-ischemic capability of the angiotensin-converting enzyme inhibitor captopril, 10 patients with acute myocardial ischemia (angina pectoris >1 h, ST-segment depression ±0.1 mV, no rise in creatine phosphokinase) received 25 mg captopril sublingually after being treated with an intravenous infusion of nitroglycerin (3 mg/h) and heparin (1200 IU/h) for 1 hour. A control group of 10 patients received placebo instead of captopril. Results showed a decrease of the initial ST-segment depression from 0.25±0.04 to 0.2±0.03 mV (p>0.01) with nitroglycerin for the captopril group and from 0.26±0.05 to 0.21±0.05 mV (p>0.01) for the control group. An additional decrease to…

AdultMaleCaptoprilAdministration SublingualCoronary DiseasePlaceboSublingual administrationAngina PectorisAnginaElectrocardiographyNitroglycerinHeart ratemedicineHumanscardiovascular diseasesMyocardial infarctionCreatine KinaseClinical Trials as Topicbiologybusiness.industryHemodynamicsCaptoprilGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureAnesthesiaAcute DiseaseVascular resistancebiology.proteinCreatine kinaseDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical cardiology
researchProduct

Chloroquine Stimulates the Mitogen-Driven Lymphocyte Proliferation in Patients with Psoriasis

1993

Chloroquine is known to exacerbate psoriasis. Since immunological stimuli are considered to be important for the pathogenesis of psoriasis, we compared the effects of chloroquine on cell-mediated immunity in 15 healthy control individuals and 15 patients with psoriasis. We employed the spontaneous and phytohemagglutin (PHA)-induced uptake of 3H-thymidine to measure lymphocyte proliferation. Chloroquine was added to the cultures at concentrations ranging from 0.022 to 220 microM. We found that both spontaneous and PHA-driven lymphocyte proliferations were significantly lower in patients with psoriasis (p0.002). The spontaneous blastogenesis in both controls and patients remained stable under…

AdultMaleCellular immunityT-LymphocytesDermatologyLymphocyte proliferationLymphocyte ActivationPathogenesisChloroquinePsoriasismedicineHumansPsoriasisPhytohemagglutininsCells CulturedAgedAged 80 and overbiologyCell growthChloroquineT lymphocyteMiddle Agedmedicine.diseaseMitogen-activated protein kinaseImmunologybiology.proteinFemaleCell Divisionmedicine.drugDermatology
researchProduct

Decision making in a presumptive case of STEMI-like myocarditis

2015

In youngmales, differential diagnosis during chest pain is not always easy. When ECG findings suggest a cardiac origin of such symptoms, myo-pericarditis is usually themost likely hypothesis, beingmore common than Acute Coronary Syndromes (ACS) in the first decades of life [1]. In the presence of ST segment elevation, Troponin release and ventricular wall motion abnormalities, the diagnosis can be challenging, though. In the young a lowcoronary risk profile and atypical symptoms seldom support a working diagnosis of Coronary Heart Disease (CHD), and, therefore, urgent coronary angiography is not recommended routinely, although cases of early ACS are not so rare. In October 2014 a 26-year-ol…

AdultMaleChest Painmedicine.medical_specialtyMyocarditisCath labClinical Decision-MakingMyocarditiPopulationMyocardial InfarctionCoronary AngiographyChest painElectrocardiographyCoronary thrombosisInternal medicinemedicineMyocardial infarctioneducationCreatine KinaseST depressioneducation.field_of_studybusiness.industrymedicine.diseaseTroponinCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessTIMIHumanInternational Journal of Cardiology
researchProduct

Temsirolimus for the treatment of mantle cell lymphoma.

2010

Although recent progress has been made in the treatment of mantle cell lymphoma (MCL) the majority of patients experience relapse and ultimately die of their disease. The translocation t(11;14) is a prerequisite for the diagnosis of MCL and results in overexpression of cyclin D1. Its protein translation is controlled by mTOR, a key element of the PI3K/Akt pathway, and mTOR constitutes an attractive therapeutic target. Temsirolimus, a specific inhibitor of mTOR, has been evaluated in two Phase II trials in patients with relapsed MCL, and promising response rates up to 40% were found. Subsequently, a randomized Phase III trial was initiated, in which superiority in remission induction and pro…

AdultMaleCombination therapyChromosomal translocationAntineoplastic AgentsLymphoma Mantle-CellPharmacologyDisease-Free SurvivalDrug Administration ScheduleCyclin D1hemic and lymphatic diseasesmedicineSecondary PreventionHumansCyclin D1PI3K/AKT/mTOR pathwayAgedAged 80 and overSirolimusClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesRemission InductionIntracellular Signaling Peptides and ProteinsHematologyMiddle Agedmedicine.diseaseTemsirolimusNon-Hodgkin's lymphomaRegimenCancer researchMantle cell lymphomaFemalebusinessmedicine.drugExpert review of hematology
researchProduct